Updated results from Celgene's CELG MM-015 study reaffirmed Revlimid's efficacy in improving progression free survival (PFS).
The analysts said, "We believe that the data will
support US and EU filing in front line MM. While US approval will likely have limited impact, as Revlimid is already widely used off label, we believe that in Europe, approval will provide an incremental $1bn opportunity."
Celgene is rated Overweight with a price target of $77.00. CELG is currently trading at $53.44.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsBiotechnologyFinancialsHealth CareM. Ian SomaiyaPiperJaffraySasha BlaugThrifts & Mortgage Finance
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in